Physician profile
Kent S Carson
NPI 1508810292
$1,421.89
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $116 · 2021: $678 · 2022: $396.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $598.62 | 2019-2022 | |
| Eli Lilly and Company | $175.00 | 2022 | |
| Pfizer INC. | $141.98 | 2019-2021 | |
| Abbvie INC. | $131.97 | 2019-2021 | |
| Janssen Biotech, INC. | $103.82 | 2021-2022 | |
| Genzyme Corporation | $69.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $67.90 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $47.25 | 2021 | |
| Sun Pharmaceutical Industries INC. | $37.96 | 2020-2021 | |
| Leo Pharma INC. | $18.08 | 2021 | |
| Incyte Corporation | $17.04 | 2021 | |
| Lilly USA, LLC | $13.25 | 2021 |
Research and ownership
$16,790.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.